Staar Surgical Shares Rise Nearly 8% After Analyst Upgrade
On Tuesday, Staar Surgical (NASDAQ: STAA) saw its stock price rise nearly 8%, driven by an upgrade from Stifel analyst Thomas Stephan. The analyst raised his recommendation for the eyecare company's shares to 'buy' from 'hold,' and increased his price target to $31 per share from $28. In a note, Stephan highlighted expected higher-than-anticipated sales in 2026, particularly driven by growth in China for Staar’s small surgically implanted lenses. Stephan also noted that the company is undervalued both as an acquisition candidate and due to its product development potential. The stock's rise reflects investor confidence in Staar Surgical's lean operations, FDA-approved products addressing common vision issues, and strong niche market positioning.
Tickers: $STAA
Topics: acquisition potential eyecare FDA approval healthcare